Danish Healthtech Stock News

Pandora A/S has released its fourth-quarter and full-year 2025 results, reporting quarterly sales of DKK 11,859 million and full-year sales of DKK 32,549 million, with earnings per share edging higher despite broadly stable net income. Alongside detailing 6% organic growth for 2025, Pandora outlined 2026 guidance, plans to reduce commodity exposure, and proposed a higher dividend with future share buybacks, underlining management’s current priorities for profitable expansion and capital...

ChemoMetec (CPSE:CHEMM) opened H1 2026 with total revenue of DKK 244.1 million, basic EPS of DKK 4.77 and net income of DKK 83.1 million, setting the tone for another closely watched update. The company has seen revenue move from DKK 208.1 million in H2 2024 to DKK 251.5 million in H1 2025 and DKK 244.1 million in H2 2025, while basic EPS over those periods shifted from DKK 3.78 to DKK 5.94 and then DKK 4.77. This gives investors a clear view of how the top and bottom lines have tracked...

Rockwool (CPSE:ROCK B) has wrapped up FY 2025 with fourth quarter revenue of €989 million and a net loss of €332 million, setting a stark contrast against earlier quarters where earnings were positive. Over the year, revenue has sat in a relatively tight range between €959 million and €989 million per quarter, while basic EPS moved from €0.54 in Q1 2025 to €0.6 in both Q2 and Q3 before the swing into loss in Q4, and trailing twelve month net income shifted from €550 million in Q4 2024 to €28...

Q1 2026 earnings snapshot and context Ambu (CPSE:AMBU B) opened its 2026 financial year with Q1 revenue of DKK 1,558 million and basic EPS of DKK 0.44, framing the latest update against a period where earnings growth and margin changes have already been in focus for investors. Over the last twelve months, the company has seen revenue move from DKK 5,391 million to DKK 6,085 million on a trailing basis, while trailing basic EPS shifted from DKK 0.88 to DKK 2.04, giving you a clearer view of...

Ringkjøbing Landbobank FY 2025 results in focus Ringkjøbing Landbobank (CPSE:RILBA) has wrapped up FY 2025 with Q4 total revenue of DKK 1,042.9 million and basic EPS of DKK 22.87, while trailing twelve month revenue came in at DKK 4.16 billion and EPS at DKK 92.86. The bank has seen quarterly revenue move between DKK 1,020.1 million in Q4 2024 and DKK 1,073.5 million in Q1 2025, with basic EPS ranging from DKK 20.68 in Q4 2024 to DKK 23.87 in Q3 2025. On a trailing view, non performing loans...

Wondering whether Carlsberg’s current share price really reflects what you are getting as an investor? This article walks through the numbers so you can judge the value for yourself. Carlsberg’s shares last closed at DKK 939.0, with returns of 10.2% over 7 days, 13.5% over 30 days, 13.7% year to date, 22.2% over 1 year, 5.9% over 3 years and 11.7% over 5 years. This provides useful context before thinking about what the stock might be worth. Recent coverage around Carlsberg has focused on...

DSV (CPSE:DSV) is in focus after reporting full year 2025 earnings that were broadly in line with guidance, alongside fresh 2026 EBIT guidance that factors in meaningful Schenker integration synergies. See our latest analysis for DSV. Alongside the 2025 earnings and fresh 2026 EBIT guidance, DSV’s share price has been strong, with a 30 day share price return of 13.42% and a 90 day gain of 31.65%. The 1 year total shareholder return of 31.15% and 5 year total shareholder return of 84.99% point...

Demant (CPSE:DEMANT) has reported FY 2025 second half revenue of DKK 11.7b with EPS of DKK 5.87, while trailing twelve month revenue stands at DKK 23.0b and EPS at DKK 11.21, setting the stage for a results season where profits and sales are both firmly in focus. The company has seen revenue move from DKK 11.3b in the second half of 2024 to DKK 11.7b in the second half of 2025, with half year EPS shifting from DKK 7.15 to DKK 5.87 and trailing twelve month EPS moving from DKK 13.31 to DKK...

Novo Nordisk (CPSE:NOVO B) has closed out FY 2025 with fourth quarter revenue of DKK 79.1 billion and basic EPS of DKK 6.05, against trailing twelve month revenue of DKK 309.1 billion and EPS of DKK 23.06. Over recent periods, the company has seen quarterly revenue range from DKK 74.9 billion to DKK 85.7 billion, with basic EPS moving between DKK 4.50 and DKK 6.54. This sets the backdrop for investors focused on how margins and earnings sustainability shape the story from here. See our full...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

Most readers would already be aware that Roblon's (CPH:RBLN B) stock increased significantly by 19% over the past three...

Insiders who purchased Dampskibsselskabet Norden A/S ( CPH:DNORD ) shares in the past 12 months are unlikely to be...

A.P. Møller - Mærsk (CPSE:MAERSK B) has resumed routing its Gemini ME11 container service with Hapag-Lloyd through the Red Sea and Suez Canal, using naval escorts to support schedule reliability on key IMEA to Mediterranean trades. See our latest analysis for A.P. Møller - Mærsk. The decision to send Gemini ME11 back through the Red Sea comes after a busy period for A.P. Møller - Mærsk, with a DKK14.4b share buy-back program underway and new leadership appointed for the IMEA region. This has...

Netcompany Group (CPSE:NETC) has wrapped up FY 2025 with Q4 revenue of DKK 2.26b and basic EPS of DKK 3.19, alongside trailing twelve month revenue of DKK 7.89b and EPS of DKK 5.48 anchoring the full year picture. Over recent quarters, the company has seen quarterly revenue move from DKK 1.68b in Q4 2024 to DKK 1.74b in Q1 2025, DKK 1.71b in Q2, DKK 2.17b in Q3 and then DKK 2.26b in Q4. EPS has ranged from DKK 2.45 in Q4 2024 to DKK 2.58, DKK 1.18, a loss of DKK 1.44, and then DKK 3.19...

Embla Medical hf (CPSE:EMBLA) has wrapped up FY 2025 with fourth quarter revenue of US$256.7 million and basic EPS of US$0.058, on trailing twelve month revenue of US$928.7 million and EPS of US$0.196 that frame the latest print. Over recent periods the company has seen revenue move from US$224.8 million and EPS of roughly US$0.044 in Q4 2024 to US$256.7 million and EPS of US$0.058 in Q4 2025, with trailing net income rising from US$68.3 million to US$83.3 million. This sets up a story where...

Demant A/S has released its full-year 2025 results, reporting sales of DKK 22,971 million, up from DKK 22,419 million a year earlier, while net income fell to DKK 1,545 million and basic earnings per share from continuing operations declined to DKK 11.2. The combination of higher sales but lower net income and earnings per share highlights shifting cost, margin or mix effects that may reshape how investors view Demant’s underlying earnings quality. We’ll now examine how Demant’s higher sales...

Novo Nordisk issued a sharp warning for 2026 sales and profit, citing intensifying U.S. price pressure, patent expiries, and rising competition. The company announced a large share buyback aimed at supporting market confidence during this period of expected financial pressure. CagriSema, a next generation diabetes and obesity therapy, reported superior Phase 3 results versus semaglutide, with pivotal regulatory filings underway. Novo Nordisk (CPSE:NOVO B), trading at DKK367.8, is drawing...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

What are the early trends we should look for to identify a stock that could multiply in value over the long term...

ISS (CPSE:ISS) has secured a full Integrated Facility Services contract with a major life sciences and pharmaceutical client in Switzerland, valued at nearly DKK 300 million annually across four locations. See our latest analysis for ISS. The contract win comes as ISS shares trade at DKK245.2, with a 30 day share price return of 13.73% and a 90 day gain of 19.49%. The 1 year total shareholder return of 81.37% and 5 year total shareholder return of 142.04% point to strong momentum that recent...

Share reduction and what it means for UIE (CPSE:UIE) investors UIE (CPSE:UIE) is set to reduce its outstanding shares on 4 February 2026, cutting the share count by 942,690 from 32,227,690 to 31,285,000. This represents a material shift in its capital structure. See our latest analysis for UIE. At a share price of DKK382.0, UIE’s recent 90 day share price return of 20.50% and 1 year total shareholder return of 28.48%, alongside a 3 year total shareholder return of 144.50% and 5 year total...

Netcompany Group A/S has reported its full-year 2025 results, with sales rising to DKK 7,891.7 million while net income decreased to DKK 256.9 million, leading to lower basic and diluted earnings per share from continuing operations. An interesting contrast for investors is that these earnings were released just after the company completed a DKK 500 million share buyback programme aimed at adjusting its capital structure and supporting share-based incentives. We will now consider how...

H. Lundbeck A/S recently presented six-month real-world data from its 12-month INFUSE study at the 2026 Headache Cooperative of the Pacific Conference in Ojai, California, highlighting outcomes for adults with migraine treated with Vyepti (eptinezumab) after prior preventive anti-CGRP failures. The data showed meaningful improvements in multiple patient-reported outcomes, including an average 6.3 additional "good days" per month, reinforcing the clinical relevance of switching to intravenous...

Genmab (CPSE:GMAB) is back in focus after reporting that worldwide net trade sales of DARZALEX, as disclosed by Johnson & Johnson, reached US$14.351b in 2025. This figure feeds directly into Genmab’s royalty income. See our latest analysis for Genmab. Genmab’s DARZALEX update lands after a strong run in the shares, with a 10.67% 90 day share price return and a 49.98% 1 year total shareholder return. However, the 3 and 5 year total shareholder returns remain negative, suggesting recent...